Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.

Dr. Stephen Hahn, former FDA Commissioner and Chief Medical Executive for MD Anderson Cancer Center, becomes CEO

Following three years of research and development, Flagship unveils Harbinger Health with $50 million of committed capital